Quick Links: Skip to main page content
Skip to Search
Skip to Topics Menu
Skip to Common Links
U.S. Food & Drug Administration
Follow FDA
En Español
Search FDA
Home
Food
Drugs
Medical Devices
Radiation-Emitting Products
Vaccines, Blood & Biologics
Animal & Veterinary
Cosmetics
Tobacco Products
New Pediatric Labeling Information Database - Detail
FDA Home
Pediatrics
New Pediatric Labeling Information Database
Detail
-
Please note:
JavaScript must be enabled for this application to work properly.
Check your settings
if you are unsure if your JavaScript is enabled.
Pediatric Labeling Date:
03/26/2020
Trade Name:
Taltz
Generic Name or Proper Name (*):
ixekizumab
Indications Studied:
Moderate-to-severe plaque psoriasis
Label Changes Summary:
*Safety and effectiveness have been established in pediatric patients 6 years to less than 18 years with moderate-to-severe plaque psoriasis. *Safety and effectiveness in other pediatric indications and for pediatric patients less than 6 years of age have not been established. *In the clinical trial, Crohn's disease occurred at a greater frequency in the treatment group (0.9%) than the placebo group (0%) during the 12-week, placebo-controlled period. Crohn's disease occurred in a total of 4 Talkz treated patients (2.0%) in the clinical trial. *Safety profile was similar to those observed in adults with plaque psoriasis with the exception of the frequencies of conjunctivitis (2.6%), influenza (1.7%), and urticaria (1.7%). *Information on dosing, adverse reactions, PK parameters and clinical trial. *Postmarketing study.
PREA(P):
P
Sponsor:
Eli Lilly
NNPS:
FALSE
Therapeutic Category:
Humanized interleukin-17A antagonist
-
-